ArticleApplied immunohistochemistry & molecular morphology : AIMM2025
The Expression and Clinical Features of 8 Immunohistochemistry Markers in Adrenal Cortical Adenomas and Pheochromocytomas.
Article in Applied immunohistochemistry & molecular morphology : AIMM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study explores the potential relationship between 8 immunohistochemistry markers and 4 adrenal diseases-cushing syndrome, primary hyperaldosteronism, nonfunctioning adrenal adenoma, and hypercatecholamine-based on symptoms and laboratory findings. Understanding these associations can provide valuable insights into the diagnosis and management of adrenal tumors. We retrospectively analyzed cases of patients treated in the urology department of our hospital from April 2017 to May 2022, focusing on pathologic results of specimens that had undergone immunohistochemical staining following laparoscopic adrenalectomy. The statistical analysis was performed using the χ 2 test with SPSS 25.0 software. A total of 124 cases were collected, including 71 men and 53 women. Among them, 21 cases were diagnosed with cushing syndrome, 49 with primary hyperaldosteronism, and 40 with nonfunctioning adrenal adenoma, all reported as adrenal cortical adenomas. In addition, 14 cases were diagnosed with hypercatecholamine, reported as pheochromocytoma. The expression of Melan-A, inhibin α, and vimentin was significantly higher in adrenal cortical adenomas compared with pheochromocytoma ( P <0.05), while CgA and S100 were more noticeable in pheochromocytoma ( P <0.05). However, there was no significant difference in the expression of Syn, β-catenin, and CK between these 2 groups. Further comparisons revealed no significant differences among cushing syndrome, primary hyperaldosteronism, nonfunctioning adrenal adenoma, and hypercatecholamine concerning these 8 markers. The same applied when comparing nonfunctioning adrenal adenoma and functional adrenal adenoma (cushing syndrome and primary hyperaldosteronism). Our findings suggest that the combination of Melan-A, inhibin α, vimentin, CgA, and S100 may be useful in distinguishing between adrenal cortical adenoma and pheochromocytoma. However, these markers are not reliable for distinguishing among cushing syndrome, primary hyperaldosteronism, hypercatecholamine, and nonfunctioning adrenal adenoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.